DURHAM, N.C. & GUANGZHOU, China, July 14, 2026
Lexitas Pharma Services and Ocusun have announced the enrollment of the first patient in a multicenter U.S. pilot study evaluating ZOC2017217, an investigational topical eye drop designed as a potential non-surgical treatment for age-related cataracts. The milestone marks an important step toward the upcoming Phase III clinical trial, advancing the development of what could become one of the first pharmacological therapies capable of slowing or potentially reversing cataract progression. The randomized, double-masked, placebo-controlled pilot study will assess the safety and efficacy of ZOC2017217 in patients with age-related cataracts, a condition affecting more than 94 million people worldwide and remaining one of the leading causes of blindness and vision impairment. The first participant was enrolled at North Bay Eye Associates in Petaluma, California, under the leadership of ophthalmologist Dr. Jason Bacharach. If successful, the investigational therapy could significantly reduce reliance on cataract surgery and provide millions of patients with a convenient, non-invasive treatment option before surgical intervention becomes necessary.
Pilot Study Advances Innovative Cataract Therapy
The ongoing U.S. pilot study serves as a critical precursor to the planned Phase III clinical trial, evaluating whether ZOC2017217 can safely improve vision and delay disease progression in patients with age-related cataracts. Developed by Ocusun, the investigational therapy is derived from lanosterol, a naturally occurring sterol that has demonstrated promising biological activity against cataract formation. Unlike existing treatment options that rely almost exclusively on surgery, ZOC2017217 is designed to reduce lens opacity, improve visual function, and potentially inhibit or reverse the molecular processes responsible for cataract development. The study follows encouraging findings from earlier exploratory clinical research conducted in China, where 50% to 86.4% of treated participants achieved visual acuity of 20/40 or better within 12 to 24 weeks, supporting continued global clinical development. Researchers believe the therapy could transform cataract management by offering patients an earlier treatment option before vision deterioration requires surgical intervention.
Clinical Research Addresses a Major Global Eye Health Challenge
According to the World Health Organization (WHO), cataracts affect more than 94 million people globally, making them one of the leading causes of blindness and visual disability. In the United States alone, cataract treatment represents approximately $3.4 to $3.6 billion in annual Medicare expenditures, reflecting the significant healthcare burden associated with surgical management. Current treatment is limited to cataract surgery, leaving no approved pharmaceutical therapy capable of delaying or reversing disease progression. Preclinical studies evaluating ZOC2017217 demonstrated improvements in antioxidant activity, inhibition of protein misfolding and aggregation, and reduced lens opacity, while early clinical observations also indicated improvements in visual function and vision-related quality of life. These encouraging findings have positioned the investigational eye drop as one of the most closely watched ophthalmology development programs seeking to expand therapeutic options beyond surgery.
Advertisement
Global Collaboration Strengthens Ophthalmic Drug Development
The collaboration combines Ocusun’s innovative ophthalmic drug discovery expertise with Lexitas Pharma Services’ specialized ophthalmology clinical research capabilities, creating a strong foundation for global clinical development. As one of the leading ophthalmology-focused contract research organizations (CROs), Lexitas provides extensive scientific, regulatory, operational, and clinical expertise across every stage of ophthalmic drug development. The partnership reflects growing investment in innovative therapies addressing significant unmet needs in vision care while supporting the development of precision treatments capable of improving long-term patient outcomes. Successful completion of the pilot study will help generate critical clinical evidence supporting the planned Phase III program, bringing ZOC2017217 closer to becoming a potential first-in-class pharmacological treatment for age-related cataracts. If clinical success continues, the therapy could redefine cataract management by expanding treatment options, preserving vision, and reducing the global burden associated with one of the world’s most common age-related eye diseases.
Source: Lexitas Pharma Services, Ocusun press release
